Adrenoleukodystrophy (ALD): investigations
Written and reviewed by Dr Ibrahim Imam, Consultant Neurologist. Last reviewed .
Adrenoleukodystrophy (ALD): investigations. C24:0/C22:0 and C26:0/C22:0 ratios: these are increased. Fully referenced neurology checklist.
Very long chain fatty acids (VLCFAs)
- C26:0: the levels are increased in plasma, cultured skin fibroblasts, and blood cells
- C24:0/C22:0 and C26:0/C22:0 ratios: these are increased
Hormone tests
Locked: subscribe to see this section.
Genetic testing
Locked: subscribe to see this section.
Magnetic resonance imaging (MRI) brain: sites of demyelination
Locked: subscribe to see this section.
Magnetic resonance imaging (MRI) brain: sites of atrophy
Locked: subscribe to see this section.
Plasma neurofilament light (NfL)
Locked: subscribe to see this section.
References
- Mukherjee S, Newby E, Harvey JN. Adrenomyeloneuropathy in patients with `Addison's disease': genetic case analysis. J R Soc Med 2006; 99:245-249.
- Kumar AJ, Köhler W, Kruse B, et al. MR findings in adult-onset adrenoleukodystrophy. Am J Neuroradiol 1995; 16:1227-1237.
- Kennedy CR, Allen JT, Fensom AH, Steinberg SJ, Wilson R. X-linked adrenoleukodystrophy with nondiagnostic plasma very long chain fatty acids. JNNP 1994; 57:759-761.
- Das G, Baglioni P, Kadiyala R. Importance of family history in patients with adrenoleukodystrophy QJM 2010; 103:628-630.
- van Geel BM, Assies J, Wanders RJ, Barth PG. X linked adrenoleukodystrophy: clinical presentation, diagnosis, and therapy. JNNP 1997; 63:4-14.
- And 8 more. Subscribe to see the full list
